Ascendis Pharma rallies after binding settlement over Yuviwel patents
Ascendis Pharma shares rose 5.7% to $262.12 on Monday. The move follows a Sunday binding settlement with BioMarin Pharmaceutical to resolve all global patent disputes regarding Yuviwel.